Ocular FIP treatment gains clarity as antiviral evidence grows

Ocular FIP is moving from a largely devastating diagnosis toward a more manageable one, as emerging clinical evidence suggests antiviral treatment can improve not just overall remission rates, but eye-specific disease as well. That’s the practical takeaway behind VetGirl’s recent podcast focus on ocular FIP, which comes as veterinarians in the U.S. continue adapting to a post-2024 landscape where compounded GS-441524 is more accessible for individual feline patients. (fda.gov)

The backdrop here is important. Feline infectious peritonitis was long considered almost uniformly fatal, and for years many U.S. pet parents sought GS-441524 through unregulated channels because no FDA-approved treatment existed. On May 10, 2024, FDA said it did not intend to enforce new animal drug approval requirements for GS-441524 compounded from bulk drug substances when prescribed by a veterinarian for a specific cat with FIP under the conditions in GFI #256. FDA also emphasized that these compounded products are still unapproved and “not, in fact, legal,” despite the agency’s enforcement discretion. Soon after, Cornell’s Feline Health Center reported that Stokes Pharmacy, working with Bova, would begin offering compounded oral GS-441524 in the U.S. on June 1, 2024. (fda.gov)

Against that regulatory shift, the ocular FIP literature is starting to fill in practical treatment questions. A 2024 observational case series on cats with ocular involvement treated with remdesivir alone or in combination with GS-441524 reported that most ocular FIP cases in the study period received 15 to 20 mg/kg once daily. Early in the series, cats received remdesivir because oral GS-441524 was not yet available; once oral GS-441524 became available in November 2021 in that setting, it became the initial antiviral in appetent cats. Notably, the authors said one cat presenting with panuveitis had rapid improvement and complete resolution of ocular signs with antiviral treatment alone during the treatment course, suggesting that systemic antiviral control may be sufficient in at least some cases without additional ocular-specific escalation. VetGirl’s review adds useful clinical context for recognizing these patients: ocular involvement is more common in non-effusive FIP than effusive disease, and in some cats uveitis is the main presenting complaint rather than a secondary finding. The podcast also highlighted the range of lesions clinicians may see, from keratic precipitates, iris color change, dyschoria or anisocoria, hyphema, hypopyon, and fibrinous exudate anteriorly to tapetal or non-tapetal retinal lesions, retinal hemorrhage, vascular tortuosity, retinal detachment, or perivascular cuffing posteriorly. These changes may be unilateral or bilateral and can be the first clue to underlying systemic infection. (pmc.ncbi.nlm.nih.gov)

The broader evidence base supports that direction, even if it’s still imperfect. A systematic review of GS-441524 studies published from 2018 through early 2024 specifically extracted outcomes for cats with aggravating signs, including ocular and neurologic disease, reflecting how central those presentations have become to treatment decision-making. Meanwhile, a 2025 Scientific Reports paper analyzing GS-441524 treatment outcomes from 2020 to 2024 found that among 259 cats with neurologic and/or ocular symptoms, 239 were successfully cured, with only two relapsing and requiring additional treatment. That paper also argued that adequate dosing is critical, and described dose increases late in treatment as a strategy used when cats improved initially but risked decline toward the end of therapy. VetGirl’s separate podcast on dosing and duration reinforces why this matters in practice: cats often look markedly better within the first week of antiviral therapy, but that early improvement does not necessarily mean the virus has been cleared from more difficult sites such as the eyes or central nervous system. That same discussion pointed to growing interest in more objective treatment-stop criteria, including serum amyloid A, alpha-1 acid glycoprotein, and albumin:globulin ratio trends, especially if higher induction dosing is being used to try to shorten total treatment time. (pmc.ncbi.nlm.nih.gov)

Expert and industry commentary has generally framed this as a major, but still incomplete, advance. Cornell described U.S. access to compounded GS-441524 as a “significant ray of hope,” especially because oral treatment is more feasible for many pet parents than injectable regimens. At the same time, FDA’s language remains a reminder that the profession is operating in a constrained middle ground: there is meaningful access, but not full approval, and office-stock use remains a separate issue under compounding guidance. That distinction matters for hospital protocols, inventory decisions, informed consent, and how clinicians communicate expectations around sourcing and follow-up. (vet.cornell.edu)

Why it matters: For veterinarians, ocular FIP is increasingly a disease where early recognition can materially change outcomes. Ocular signs such as uveitis, panuveitis, keratic precipitates, retinal changes, or anisocoria may no longer signal only poor prognosis; they may instead identify cats that need prompt, appropriately dosed antiviral therapy and close reassessment. The emerging literature also reinforces a practical point many clinicians have already suspected: ocular and neurologic cases may need more aggressive dosing strategies and more individualized monitoring than uncomplicated effusive disease. Weight gain, clinical improvement, laboratory trends, and imaging remain important markers of response, but in ocular cases, serial ophthalmic exams may become just as valuable in guiding whether treatment intensity is adequate. Broader VetGirl coverage on FIP diagnostics also serves as a reminder that these cases still begin with a presumptive diagnosis built from signalment, risk factors, clinicopathologic patterns, effusion characteristics when present, and compatible imaging or ophthalmic findings rather than a single definitive in-clinic test. (pmc.ncbi.nlm.nih.gov)

There are still important gaps. Much of the literature remains observational, protocols vary by country and product access, and some treatment recommendations are still being refined through clinical experience rather than head-to-head trials. Even so, the direction of travel is clear: ocular involvement does not appear to preclude remission, and legitimate veterinary prescribing pathways in the U.S. have lowered one of the biggest barriers to care. For practices, that means the conversation is shifting from whether treatment is possible to how best to diagnose, dose, monitor, and counsel. (pmc.ncbi.nlm.nih.gov)

What to watch: The next phase will likely center on standardized protocols for ocular and neurologic FIP, more comparative data on remdesivir versus GS-441524, relapse management, and whether U.S. real-world prescribing data support shorter, higher-dose, or more tailored treatment courses for cats with eye involvement. Expect added attention to objective criteria for ending therapy, not just visible improvement, as clinicians try to balance cost, duration, and relapse risk in patients with ocular or CNS disease. (pmc.ncbi.nlm.nih.gov)